Celltrion
June 16, 2025
Company Presentation
Other
CELLTRION was established in 2002, starting as a small CMO start-up company. Within just 20 years, we grew to become a global biopharmaceutical company with Sales profit reaching up to nearly 3 billion USD in 2024. And perhaps, we are best known to be the first pioneer company to commercialize bio similar in global market. Including our latest bio similar, Zymfentra for treating Rheumatoid Arthritis and inflammatory bowel disease, we have total 6 original biosimilar products approved from both FDA and EMA for global distribution. Our ambition to become a global player in world market drives us to explore the new frontier of technology. And CELLTRION global R&D center is a collection of our most advanced research infrastructure, housing 700 life-science experts to lead various research for discovering novel target and new drugs. Also we are open to collaboration with various entities including start ups, acaedmics, institutes, and government to expand our research and business boundary.
Company HQ City:
Incheon
Company HQ Country:
Korea, Republic of
Year Founded:
2002
Lead Product in Development:
Remsima, Herzuma, Truxima, Zymfentra, Yuflyma, Vegzelma, Steqeyma, Avtozma
CEO
Jinseok Seo
Development Phase of Lead Product
Multiple Products in Market
Exchange
KRX (Korea Exchange)
Ticker
068270
When you expect your next catalyst update?
4 new biosimilars to be launched in 2025
Target Revenue: KRW 5 trillion
What is your next catalyst (value inflection) update?
December 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}